194,181 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Ieq Capital LLC

Ieq Capital LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 194,181 shares of the biotechnology company’s stock, valued at approximately $6,466,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Seizert Capital Partners LLC increased its holdings in shares of Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after acquiring an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC grew its position in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in Exelixis during the 3rd quarter valued at approximately $4,396,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Exelixis by 60.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Exelixis during the third quarter worth $577,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EXEL has been the topic of several research reports. Guggenheim reissued a “buy” rating and issued a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Brookline Capital Management started coverage on Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. UBS Group raised their price objective on Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a research report on Thursday, January 23rd. Finally, BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.24.

Insider Activity at Exelixis

In other Exelixis news, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the transaction, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. 2.85% of the stock is owned by corporate insiders.

Exelixis Stock Up 0.1 %

EXEL stock opened at $35.09 on Friday. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $37.59. The firm has a market cap of $9.82 billion, a P/E ratio of 19.82, a PEG ratio of 1.10 and a beta of 0.53. The company’s 50-day simple moving average is $34.16 and its 200-day simple moving average is $31.14.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.